Document 0902
 DOCN  M94A0902
 TI    Periods from AIDS onset to death in Japanese hemophilia patients
       infected with HIV-1.
 DT    9412
 AU    Tastunami S; Meguro T; Mimaya J; Yamada K; Yago N; St. Marianna Univ.
       School of Med., Kawasaki, Japan.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):254 (abstract no. PC0382). Unique
       Identifier : AIDSLINE ICA10/94371673
 AB    The knowledge on periods from onset of AIDS to death of the patient
       should supply important information for the HIV/AIDS epidemiology. Using
       a data base constructed by Natural History Committee affiliated to The
       Research Committee on Prevention of Developing Illnesses and Therapy for
       HIV Infected Patients (Chairman: YAMADA, K) that has been sponsored by
       the Japanese Ministry of Health and Welfare, we computed by the
       Kaplan-Meier method the time-dependent survival ratio of AIDS patients.
       We could find in the data base 31 patients with both dates of onset and
       death recorded, and 67 patients with only onset dates. We divided these
       98 patients into two groups, i.e. 31 patients who had their incidence
       dates before December 1989 as Group 1 and 67 patients who had them after
       January 1990 as Group 2. In Group 1, the 50% survival point was 3.6
       years after AIDS onset, while in Group 2 it has not been attained yet.
       No significant difference has not been noticed up to now between the
       survival curves of the two Groups when examined by the generalized
       Wilcoxon test. In both Groups, AZT was used for more than 50% of the
       patients. In Group 1 ddI was used for 6% of the patients, while in Group
       2 for 17%. Improvement of the survival curve that was originally
       expected for the usage of ddI has not been clearly observed, because the
       observation periods for the patients in Group 2 have been still only
       about 3 years. However, the value of 50% survival point found in Group
       1, i.e. 3.6 years, will serve as an important parameter in estimating
       prognoses of patients infected with HIV-1.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY/*MORTALITY
       Hemophilia/*COMPLICATIONS  Human  Japan/EPIDEMIOLOGY  Prognosis
       Survival Rate  Zidovudine/THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).